Stay updated on Pembrolizumab & Endocrine Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Endocrine Therapy Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2; the 'Back to Top' link was removed.
    Difference
    0.1%
    Check dated 2025-09-14T18:49:27.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.
    Difference
    0.1%
    Check dated 2025-09-07T13:26:21.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as new drug information for Fulvestrant, Letrozole, Palbociclib, and Pembrolizumab. However, several related topics and drug classifications have been removed, which may affect the comprehensiveness of the content.
    Difference
    3%
    Check dated 2025-08-31T11:16:19.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.11 to version 2.16.12.
    Difference
    0.0%
    Check dated 2025-08-17T00:41:01.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.10 to version 2.16.11.
    Difference
    0.0%
    Check dated 2025-08-09T20:07:26.000Z thumbnail image
  7. Check
    48 days ago
    Change Detected
    Summary
    The web page has been updated to include a new clinical trial for a combination treatment involving pembrolizumab, letrozole, and palbociclib for postmenopausal patients with metastatic estrogen receptor positive breast cancer. Additionally, the page now includes a disclaimer about the U.S. government's non-review of all studies listed.
    Difference
    100%
    Check dated 2025-08-02T15:04:44.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Endocrine Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Endocrine Therapy Clinical Trial page.